Sun Pharma receives USFDA approval for generic lenalidomide Capsules
In June 2021, Sun Pharma had entered into a settlement with Celgene Corporation (Celgene) to resolve the patent litigation regarding Sun Pharma's generic lenalidomide capsules. Pursuant to the terms of this
settlement, Celgene granted Sun Pharma a license to Celgene's patents required to manufacture and sell certain limited quantity of generic lenalidomide capsules in the US beginning sometime after March
2022. In addition, the license allows Sun Pharma to manufacture and sell an unlimited quantity of generic lenalidomide capsules in the US beginning 31 January 2026.